Karen Sinclair

Pharmacokinetics of Nilotinib in Pediatric Patients with Philadelphia Chromosome–Positive Chronic Myeloid Leukemia or Acute Lymphoblastic Leukemia

Nobuko Hijiya, C. Michel Zwaan, Carmelo Rizzari et al. · Clinical Cancer Research · 2019 · 32 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +14

Concomitant Use of Midostaurin with Strong CYP3A4 Inhibitors: An Analysis from the Ratify Trial

Taoufik Ouatas, Vincent Duval, Karen Sinclair et al. · Blood · 2017 · 24 citations

Medicine, Pharmacokinetics, Pharmacology +6

Evaluation of drug–drug interactions between midostaurin and strong CYP3A4 inhibitors in patients with FLT-3-mutated acute myeloid leukemia (AML)

Romain Séchaud, Karen Sinclair, Kai Grosch et al. · Cancer Chemotherapy and Pharmacology · 2022 · 23 citations

Medicine, Pharmacokinetics, Pharmacology +16

Ruxolitinib in treatment-naive or corticosteroid-refractory paediatric patients with chronic graft-versus-host disease (REACH5): interim analysis of a single-arm, multicentre, phase 2 study

Franco Locatelli, Bülent Antmen, Hyoung Jin Kang et al. · The Lancet Haematology · 2024 · 16 citations

Life Sciences, Clinical Sciences, Pediatrics +12

Efficacy and safety of ruxolitinib in patients with myelofibrosis and low platelet count (50 × 10 ⁹ /L to <100 × 10 ⁹ /L) at baseline: the final analysis of EXPAND

Paola Guglielmelli, Jean‐Jacques Kiladjian, Alessandro M. Vannucchi et al. · Therapeutic Advances in Hematology · 2022 · 11 citations · Full text

Medicine, Hematology, Pharmacology +16